Posts With Tag China pharmaceutical

Explore Universe Pharmaceuticals INC's Form 6-K report detailing the adjournment of the February 2025 extraordinary general meeting and compliance with SEC regulations.

Explore HUTCHMED's latest Form 6-K, detailing a $608M joint venture divestment and NDA acceptance for ORPATHYS® in China. Key updates for investors and stakeholders.